Kidney transplantation
Immunosuppression regimens, belatacept, mTOR conversion and HCV-positive donors.
- Trials
- 6
- Years
- 2007–2024
Sort
- 2024Felzartamab AMRAntibody-mediated rejectionIn 22 kidney-transplant recipients with chronic active antibody-mediated rejection, felzartamab resolved rejection morphology more often than placebo.82% vs 20%Read →
- 2018TRANSFORMmTOR inhibitorsIn 2,037 de-novo kidney-transplant recipients, everolimus with reduced calcineurin inhibitor was non-inferior for rejection, graft loss or death compared with mycophenolate with standard calcineurin inhibitor.48.2% vs 45.1%Read →
- 2017THINKERHCV-positive donorsIn 20 HCV-negative recipients of hepatitis-C-viraemic donor kidneys, antiviral therapy achieved a sustained virologic response in every patient.Read →
- 2016BENEFITBelataceptIn 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.HR 0.5795% CI 0.35-0.95Read →
- 2011ZEUS 2011mTOR inhibitorsIn 300 kidney-transplant recipients, early conversion from ciclosporin to everolimus improved kidney function compared with continued ciclosporin.Read →
- 2007ELITE-Symphony CoreImmunosuppressionIn 1,645 kidney-transplant recipients, low-dose tacrolimus with mycophenolate and steroids gave better graft function than the other immunosuppressive regimens.Read →